Replimune Group, Inc. received accelerated approval for TUDRIQEV™ in advanced melanoma, while its stock price reflected quarterly EPS misses.
2 reports, 2 independent
Updated Wed 00:00
No new developments lately
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Replimune Group, Inc. received accelerated approval for TUDRIQEV™ in advanced melanoma, while its stock price reflected quarterly EPS misses.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Replimune launched TUDRIQEV as primary therapy and named Emily Hill as CFO.1 source
Replimune Group received accelerated FDA approval for TUDRIQEV™ for advanced melanoma.1 source